Non-invasive gene delivery for expression of therapeutic genes in oligodendrocytes: A new strategy to treat myelin diseases.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1050277

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

White matter diseases are debilitating childhood disorders caused by defects in the insulating myelin sheath normally covering and protecting the nerve fibres from damage. There is currently no effective treatment but the delivery of a genetic medicine to the diseased myelin forming cells in the brain could be curative. This project aims at establishing the safe, efficient and non-invasive delivery of therapeutic genes to myelin forming cells as a gene therapy for white matter disorders.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $594,393.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Gene and Molecular Therapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

adeno-associated virus | gene therapy | gene transfer | metabolic disorders | myelin | neurological disorders | oligodendrocytes

Related Links